The age-related decline in growth hormone (GH) secretion has been largely attributed to age-related degeneration of hypothalamic growth hormone-releasing hormone (GHRH)-producing neurons. GH decline has recently been linked to age-related bone changes in humans. Bone loss and decreased bone strength are common in aging rats and humans, but density of remaining mineral tissue is known to be increased. The effect of induced hypothalamic GHRH deficiency on bone was assessed, and similarities between bone changes encountered and those taking place in aging were identified. Female rats received monosodium glutamate (MSG) following birth, and they were euthanized at 19 weeks of age. Femurs from MSG-treated rats had greater mineral density (p < .05), greater mineral! matrix ratio (p < Ml), lower mineral apposition rate (p < .005), and lower bone formation rate (p < .05). These results suggest that hypothalamic GHRH decline plays a substantial role in the development of bone pathology similar to that observed in aging individuals.
'T'HE involvement of growth hormone (GH) in the devel--^ opment and maintenance of bone is extensive. It is well known that bone formation and resorption are stimulated by GH (Harris et al., 1972; Kiess et al., 1986) , which directly promotes longitudinal bone growth through stimulation of chondrocytes and osteoblasts (Isaksson et al., 1987) . Bone metabolism is indirectly influenced by the effect of GH on the immune system (Kiess et al., 1986) , sex steroids (Jansson et al., 1985) , and parathyroid hormone (Hock and Fonseca, 1990) .
The indirect action of GH is primarily via insulin-like growth factor-I (1GF-I) (Stracke et al., 1984; Ernst and Froesch, 1988) , which mediates the local effect of GH in bone (Stracke et al., 1984; Schmid et al., 1989) . Perhaps the most abundant growth factor secreted by bone (Chen et al., 1991; McCarthy et al., 1991) , IGF-I directly increases long bone growth (Tobias et al., 1992) by stimulating chondrocytes in the growth plate (Isaksson et al., 1987) and increasing DNA, protein, proteoglycan, and collagen synthesis (Froesch et al., 1985; Hock and Fonseca, 1990) . IGF-I increases the circumference of long bones (Tobias et al., 1992) by stimulating osteoblastic periosteal bone formation (Ernst and Froesch, 1988) , thereby contributing to increased mechanical strength (Baron et al., 1983) .
IGFs in the serum and interstitial tissues are bound to a group of IGF binding proteins (IGFBPs), which modulate IGF bioavailability and augment the action of IGF-I in bone tissue Ernst and Rodan, 1990) . GH stimulates synthesis of IGFBP-3, the largest and most abundant of these proteins Jorgensen et al., 1990) , and facilitates the accumulation of IGFBP-3 by osteoblasts (Schmid etal., 1989) .
While declines in serum GH are a common finding among older individuals (Prinz etal., 1983; Takahashi etal., 1987) , the exact etiology of GH and GH-dependent growth factor deficiency is currently under speculation. There is increasing evidence that higher neuroendocrine regulatory centers are involved in these changes. Principal neuroregulators of pituitary GH are growth hormone-releasing hormone (GHRH) and somatostatin; the former stimulates, whereas the latter inhibits GH release. Declines in GH secretion are a result of diminished GHRH synthesis and release (Matsumoto and Arai, 1983; Peng, 1983; Morimoto et al., 1988) , and possibly increased somatostatin release (Sonntag et al., 1986; Meites, 1988) . This hypothalamic dysfunction in rats and humans is attributed to decreased hypothalamic norepinephrine and dopamine content (Hornykiewicz, 1987; Meites, 1988) and chronic exposure to free radicals and hormones (Brawer etal., 1978; Meites, 1988) .
Experimental studies have documented decreased serum levels of GH, IGF-I, IGF-II, and IGFBP-3 in women with postmenopausal osteoporosis (Smith, 1967; Rico etal., 1979; Dequeker et al., 1982; Wuster et al., 1991) . Despite the fact that osteoporosis leads to bone loss, an increase in mineral density of the remaining bone is a frequent finding (Dickenson et al., 1981) . Increasing bone mineral density with age is not limited to those with osteoporosis. It appears to be a common finding among aging individuals (Parfitt, 1988) , and ultimately results in decreased strength and increased susceptibility to fracture (Duncan and Parfitt, 1984) .
We hypothesize that age-related GHRH deficiency participates in the aging-associated changes in bone structure. In an attempt to further clarify bone changes resulting specifically from such neuroendocrine disruption, a GHRH deficiency state was induced in female rats. Young rats were used in order to eliminate other systemic age-related changes. Administration of monosodium glutamate (MSG) to neonatal rodents produces specific lesions in the hypothalamic arcuate nuclei (Olney, 1971 ; Simsonetal., 1977) , and destroys most of the GHRH-producing neurons (Acs et al., 1982; Bloch et al., 1984; Thompson et al., 1994) . Such lesions simulated age-related hypothalamic neuronal degen-
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eration, and GHRH in particular was reduced throughout the life span of the animals. Of primary interest were resultant changes in bone size, strength, mineral and connective tissue content and density, as well as histomorphometric alterations. Like the documented aging-associated changes in bone, MSG-induced reduction in GHRH resulted in decreased trabecular bone formation, disruption in rate of bone turnover, and relative hypermineralization.
METHODS
Pregnant Sprague-Dawley rats were maintained in a controlled temperature (24-26 °C) and light (0600 to 1800 h daily) regulated room. Rat chow and water were available ad libitum. Female offspring received 4 mg MSG/g, sc on alternate days for the first 9 days following birth (5 injections total). Control animals received an equivalent volume of 0.9% buffered saline. Pups were weaned at 21 days of age and housed 6-7 per cage. At week 13, animals were recaged to 1 per cage.
At 10 and 3 days before euthanasia, each rat was injected with Calcein (8 mg/kg, ip) for later histomorphometric analysis. At 19 weeks of age, the naso-anal length of each rat was determined. Animals were euthanized and immediately perfused through the left ventricle with heparinized saline followed by 10% paraformaldehyde. Pituitary glands were immediately harvested, weighed, homogenized in 1 ml buffered saline, and subsequently frozen until later GH immunoassay. Adrenals, kidneys, gonads, right femurs, and right humeri were manually resected, cleaned of connective tissue, and stored in 10% paraformaldehyde at room temperature for later analysis. Left femurs were similarly harvested, cleaned, and placed in 70% ethanol for later slide preparation.
Pituitary growth hormone assay. -Pituitary homogenates were tested for GH content with a rat growth hormone (rGH) [ 125 I] radioimmunoassay system (Amersham International, Little Chalfont, UK). The assay has a sensitivity of 1.7 ng/tube, with intra-and interassay coefficients of 3% and 10.5%, respectively.
Organ weights and bone strength. -Each set of organs was blotted dry and weighed as a pair to the nearest mg. Digimatic calipers (Mitutoyo, Tokyo, Japan) were used to obtain three-dimensional measurements of the right femur and humerus to the nearest .01 mm. A three-point compression bend test of right femur strength was carried out on an Instron Model 1000 universal testing instrument (Instron Corp., Canton, MA) . Force values obtained reflect the minimum force required to fracture the bone when applied mid-shaft and parallel to the line of mid-shaft diameter.
Bone tissue densities. -Diaphyseal bone fragments from the right femurs were cleaned of marrow and cut into 5mm segments for estimation of total bone density (Martin and Gutman, 1978) , as well as mineral and matrix densities. In addition, the ratio of mineral to matrix content of each segment was determined (Mueller etal., 1966) . During bone preparation, care was taken to ensure that segments were obtained from the diaphyseal area, no more than 5mm from midshaft. Following sectioning into segments, each was weighed to obtain a wet weight (WW). Segments were then weighed while suspended in distilled water (|xs) for calculation of bone volume. Segments were dehydrated in 100 percent ethanol for 48 h, allowed to dry for 24 h, and weighed again for determination of the defatted dry weight (DDW). Ash weight was determined after incineration in a muffle furnace (600 °C for 24 h). The following formulas were utilized to estimate bone tissue densities: (Martin and Gutman, 1978 ) (Martin and Gutman, 1978) DDW-AW (Mueller etal., 1966) where WW = wet weight; DDW = defatted dry weight; pH 2 O = density of water; JJLS = weight of bone segment when submerged in water; and AW = ash weight (weight of bone segment after muffle furnace).
Real densities reflect the density of the tissues excluding water, vascular channels, and lacunae, whereas apparent densities are the density of tissues including water, vascular channels, and lacunae.
Histomorphometric analysis of femur bones. -Left femur bone fragments were embedded undecalcified in methylmethacrylate and cut longitudinally on a Jung microtome into 14 fxm sections for analysis of proximal metaphyses/distal epiphyses. Bone histomorphometry was performed using a transmitted and epifluorescent fight microscopy linked to computed-assisted image analyzer (Tobias et al., 1992) . Bone volume and surface parameters were measured by tracing relevant features with a cursor on the video screen image. A 10-12 mm 2 rectangular data collection area was outlined on each slide by a felt-tip pen. The area studied consisted only of trabecular bone. Trabecular bone volume (TBV) was expressed as the percentage of tissue volume composed of mineralized bone. Trabecular bone surface with single (sLS) and double (dLS) calcein labels was expressed as a percentage of trabecular bone surface. The mineral apposition rate (MAR), a measure of individual osteoblast activity, was the mean interlabel distance divided by the time interval (days) between relevant label administrations. The bone formation rate (BFR) was calculated as the product of the MAR and dLS.
Statistical analysis. -Significant differences between groups were determined using one-way analysis of variance (ANOVA) and two-way ANOVA followed by the StudentNewman-Keuls test.
RESULTS
By the end of the first week, MSG-treated animals weighed less than the controls (p < .01) (Figure 1 ). This significant difference in weight was observed between groups until week 9, at which time body weight of the MSG group began to rise more rapidly. At euthanasia, rats in the MSG group outweighed the controls, but this difference is not significant (Figure 1) .
MSG treatment led to 71 % reduction in pituitary weight at 19 weeks (p < .05), but had no appreciable effect on total pituitary GH (Table 1) . When corrected for pituitary weight, pituitary GH content was increased in the MSG-treated animals, but without statistical significance (Table 2) . Although slightly less in weight, kidneys from experimental animals were not statistically different from controls (Table 2) . When corrected for body weight, however, kidneys of MSG rats were significantly less in weight (p < .05) ( Table 2) . Naso-anal length of MSG-treated animals was 10% less than that of controls (p < .001) (Table 3) . MSG treatment resulted in a 10% reduction in femur length and an 11% reduction in humerus length (p < .001); as a function of naso-anal length, however, no significant differences were seen (Table 3) . MSG treatment produced decreased maximum and minimum mid-shaft diameters of femur and humerus bones (p < .01-p < .05) ( Table 3) . Femoral crosssectional area was reduced 7% in experimental animals (Table 4 ). Femur fracture force was decreased by 18% in the MSG group (p < .01), but no difference is observed when calculated as a function of cortical cross-sectional area (Table 4) . Apparent total bone, mineral, and matrix densities were all increased 20-26% among MSG-treated animals (p < .05) ( Table 4 ). Real total bone and mineral densities were increased 44-50% in MSG animals (p < .05). There was no significant difference in real matrix density between groups (Table 4 ). The ratio of mineral to matrix content in femur bones was increased 5% in MSG-treated animals (p < .01) ( Table 4 ). Note. Analysis done on bones from rats 119 days of age. Values given are the mean ± SE. Multiple measurements were taken to the nearest 0.01 mm with a digimatic caliper, and an average value was obtained for each rat. *p < .01 and **p < .001 vs controls. Note. Analysis done on bones from rats 119 days of age. Values given are the mean ± 5£. Apparent densities are the density of the bone tissue including lacunae, vascular channels, and water, whereas real densities are the density of the bone tissue excluding lacunae, vascular channels, and water. Total bone densities include both bone mineral and bone matrix. *p < .05 and **/; < .01 vs controls.
Bone trabecular volume was decreased by 29% in MSGtreated animals (Table 4) . Percent of trabecular surface with single label was decreased 26% in MSG animals, but without statistical significance (Figure 2 ). There was a 58% reduction in the relative amount of trabecular bone surface with double labels (p < .05) (Figure 2 ). MSG-treated animals had a 48% reduction in bone mineral apposition rate (p < .005) (Figure 3 ) and an 82% reduction in bone formation rate (p < .05) (Figure 3) .
DISCUSSION
For over two decades, investigators have used neonatal MSG in rodents to study hypothalamic and pituitary function (Olney and Ho, 1970; Nemeroff et al., 1977; Wakabayashi et al., 1986; Maiter et al., 1991) . The central neurotoxic mechanism of MSG is now well-known (Jennes et al., 1984) . After penetrating the underdeveloped blood-brain barrier, MSG accumulates in specific areas and destroys neurons in the basal hypothalamus (Olney et al., 1976; Nemeroff et al., 1977) . The region most affected by MSG is the arcuate nucleus (Olney and Ho, 1970; Jennes et al., 1984) , the principal producer of hypothalamic GHRH (Bloch et al., 1983a (Bloch et al., , 1983b . Hypothalamic somatostatin is spared by MSG treatment (Maiter et al., 1991) . Also, altered by MSG treatment are the preoptic area and a portion of the ventromedial nucleus (Tanaka et al., 1978) . Such lesions result in chronically depressed serum GH levels as a consequence of: (a) reduced hypothalamic GHRH production and secretion Bloch et al., 1984; Merchenthaler et al., 1986) , and (b) diminished pituitary GH secretion in response to GHRH (Maiter et al., 1991) . Figure 2 . Percent of femoral trabecular surface with single calcein label (sLS) and double calcein label (dLS) in control and MSG-treated animals. Calcein (8 mg/kg, ip) was injected 10 and 3 days prior to euthanasia. Data are the mean ± SE(n = 6 for controls and n = 7 for MSG-treated groups). *p < .05. /day) is the product of MAR and percentage of trabecular bone surface with double calcein labels (dLS). Calcein labels (8 mg/kg, ip) were injected 10 and 3 days prior to euthanasia. Data are the mean ± SE (« = 6 for controls and n = 7 for MSG-treated groups). *p < .05 and **p < .005.
SINGLE LABEL DOUBLE LABEL
The neurotoxic effects of MSG on neonatal rodents are not limited solely to the somatotroph axis. MSG leads to estrous cycle irregularity and infertility in some (Olney, 1969; Holzwarth-McBride et al., 1976; Bakke et al., 1978) , but not all (Adamo and Ratner, 1970; Prosky and O'Dell, 1972; Trentini et al., 1974) studies. The effect of neonatal MSG treatment on luteinizing hormone (LH) secretion in rats is controversial. Basal LH secretion has been shown to be increased Dalkin et al., 1985) ; decreased (Dyer et al., 1981; Sridaran et al., 1981; Inkster andWhitehead, 1987; Fagbohunetal., 1990) and unaffected (Nemeroff et al., 1977; Bakke et al., 1978; Nemeroff et al., 1978; Badger et al., 1982; Lamperti and Baldwin, 1982; Rodriguez-Sierra et al., 1982; Inkster et al., 1985) by MSG administration. Similarly, AP LH contents are either unchanged (Lamperti et al., 1982; or diminished (Redding et al., 1971; Badger etal., 1982; Rodriguez-Sierra etal., 1982; Fagbohun et al., 1990) in MSG-treated female rats. In most studies, the regulation of pulsatile LH secretion remains intact following MSG administration, perhaps as a result of hypothalamic neuroendocrine reorganization (Rose and Weick, 1987) . AP and basal serum levels of folliclestimulating hormone (FSH) appear unaffected by the MSG treatment (Bakke et al., 1978; Greeley et al., 1978; Nemeroff et al., 1981; Badger et al., 1982; . Seventeen (3-estradiol levels appear to be depressed in MSG-treated female rats (Nemeroff et al., 1981) , and ovaries from treated rats are clearly reduced in size (Redding et al., 1971; Trentini et al., 1974; Inkster and Whitehead, 1987) .
The effect of neonatal MSG administration on thyroid weight is controversial (Redding et al., 1971; Nagasawa et al., 1974; Trentini et al, 1974; Bakke et al., 1978) . Serum and AP thyroid-stimulating hormone (TSH) remain unchanged following MSG treatment (Nemeroff et al., 1977 Bakke et al., 1978) . Neonatal MSG administration appears to result in decreased serum free thyroxin index (Nemeroff et al., 1977 , T4 levels (Bakke et al., 1978) , and T3 levels (Nemeroff et al., 1977 .
The significant impact of MSG on GHRH and GH regulation appears well accepted: neonatal MSG administration results in hypothalamic GHRH depletion and chronically depressed serum GH levels. The effects of MSG on the gonadotropin and thyroid axes are not fully understood and are controversial at the present time. The potential disruption in thyroid regulation may have had a slight impact on bone changes encountered in this study. As gonadal hormones are important to bone growth and homeostasis (Sledge, 1967) , the lower 17 P-estradiol levels in MSG-treated animals likely had an impact on bone in this investigation. However, such changes are not entirely unwelcome as aging females are known to have lower ovarian estradiol release, resulting in depressed serum estradiol levels (Smith, 1967; Rico et al., 1979; Dequeker etal., 1982) .
The effect of MSG on body weight of female rats is well documented, and results of this study are in concordance with previous findings (Bakke et al., 1978; Badger et al., 1982; Corder etal., 1990; Maker etal., 1991; Thompson et al., 1994) . While it is clear that pituitary weight is reduced by MSG (Bakke etal., 1978; Wakabayashi et al., 1986; Maiter et al., 1991) , pituitary GH content following MSG treatment has produced conflicting results (Redding et al., 1971; Millard et al., 1982; Wakabayashi et al., 1986; Corder et al., 1990; Maiter et al., 1991; Thompson et al., 1994) . In the present study, neonatal MSG administration had no resultant impact on pituitary GH content, suggesting GH synthesis and storage is spared following MSG treatment. In previous investigations, MSG administration led to reduced kidney, gonad, and adrenal weights (Bakke et al., 1978; Badger et al., 1982) , and the present results support these findings.
Long bone and body length are known to be reduced by neonatal MSG treatment (Maiter et al., 1991) . In the current investigation, these parameters were markedly reduced by MSG treatment. The lack of difference in bone length when corrected for naso-anal length suggests that hypothalamic GHRH deficiency results in proportionate retardation of appendicular and axial skeletal growth. Bone changes that are encountered are most likely a result of depressed GH levels and resultant diminution in GH-mediated growth factor activity. The production and activity of circulating growth factors such as IGF-I are largely dependent on GH (Stracke et al., 1984; , and these factors are known to be reduced in the MSG-induced GHdeficiency state (Maiter et al., 1991) . In long bones such stunting is likely due to diminished GH-mediated chondrocyte and osteoblast stimulation in the region of the growth cartilage. The MSG-induced reductions in long bone diameter and cortical area are probably a result of chronic GH deficiency on periosteal bone formation by osteoblasts.
Femoral fracture force was reduced by MSG treatment. This finding may be explained by a lower diaphyseal crosssectional area, since fracture force as a function of cortical cross-sectional area was not statistically different from control animals. (As strength testing evaluated a composite of ultimate compressive and tensile forces, differences in bone trabecular content may have played a role in the altered fracture force observed.) Alterations in mineral and matrix content probably influenced bone strength in experimental animals.
Mineral and matrix densities were increased in the present study; consequently, neonatal MSG treatment led to hypermineralization of diaphyseal bone and produced more compact connective tissue architecture. Bones from MSG animals had an increased mineral-to-matrix ratio, highlighting the greater relative bone mineral content in chronically GHRH-deficient rats.
Several possible explanations for the current bone findings exist, as MSG administration may result in: (a) diminished bone formation/resorption rates by decreased osteoblast and/or osteoclast stimulation; (b) alterations in bone matrix formation by osteoblasts with resultant changes in mineralization; (c) changes in the orientation or particle size (hydroxyapatite crystals) of the mineral phase (Chatterji et al., 1981) ; and (d) a generalized form of micropetrosis. Osteoblast activity, a reflection of mineral apposition rate, was indeed depressed in experimental animals. This finding further supports the theory that GHRH deficiency results in disruption of the osteoblast/osteoclast (bone formation/ resorption) balance, and contributes to the resultant hyperdense osseus state.
Bone density and histomorphometric findings in the present study may indeed link aging-associated GHRH deficiency (and resultant GH deficiency) with age-related bone changes. It is currently believed that impaired regulation of osteoblast function by one or more growth factors is a substantial element in the development of osteoporosis (Centrella and Canalis, 1985; Wiister et al., 1993) . While osteoporosis involves an increase in porosity and an overall loss of bone, the remaining bone tends to become hypermineralized, as the density of mineral per unit volume of bone (exclusive of porosities) actually increases with age (Parfitt, 1988) . Mineral content of bone from aging humans and rats with and without osteoporotic changes is known to be increased (Dickenson et al., 1981) , while rates of collagen synthesis and trabecular bone formation are decreased (Indrekvam et al., 1991) . Reid and Boyde reported that the amount of low-density bone tissue decreases with age, while the proportion of bone with a higher mineralization density increases, being contained within a smaller fraction of the skeleton (Reid and Boyde, 1987) . Compositional changes in bone lead to significant mechanical consequences as hypermineralization bone is associated with increased brittleness and increased susceptibility, fatigue, and fracture (Frost, 1960; Duncan and Parfitt, 1984) .
In conclusion, neonatal MSG administration to female rats leads to significant alterations in long bones. These changes, which are attributed primarily to the resultant GH deficiency, include depression of longitudinal and radial bone growth, trabecular bone formation, overall bone formation rate, and ultimate fracture force. MSG treatment also leads to relative hypermineralization of the diaphyseal bone. Similar osseous alterations are documented among aging rodents and humans. These results suggest that hypothalamic GHRH decline plays a substantial role in the development of bone pathology that is similar to that observed in aging individuals.
